AURORIX

This brand name is authorized in Australia, Austria, Estonia, Finland, Germany, Hong Kong SAR China, Malta, Netherlands, New Zealand, Poland, Turkey.

Active ingredients

The drug AURORIX contains one active pharmaceutical ingredient (API):

1	Moclobemide UNII PJ0Y7AZB63 - MOCLOBEMIDE
	Moclobemide is an antidepressant which affects the monoaminergic cerebral neurotransmitter system by means of a reversible inhibition of monoamine oxidase preferentially of type A (RIMA).
	Read more about Moclobemide

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N06AG02	Moclobemide	N Nervous system → N06 Psychoanaleptics → N06A Antidepressants → N06AG Monoamine oxidase A inhibitors
Discover more medicines within N06AG02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1900B, 8003F
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00202502, 00210884, 04275260, 04275277, 07258285, 07266528
EE	Ravimiamet	1421929, 1601918, 1764840
FI	Lääkealan turvallisuus- ja kehittämiskeskus	466813, 587857
HK	Department of Health Drug Office	35868
MT	Medicines Authority	AA565/56901, AA565/56902
NL	Z-Index G-Standaard, PRK	33340, 42978
NZ	Medicines and Medical Devices Safety Authority	3573, 3574
PL	Rejestru Produktów Leczniczych	100008323, 100053513
TR	İlaç ve Tıbbi Cihaz Kurumu	8699525094582, 8699525094599